Autolus Therapeutics to Participate in Conferences During April 2022
Rhea-AI Summary
Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in three notable investor conferences: the Wells Fargo Annual Biotech Forum on April 12-13, the 21st Annual Needham Virtual Healthcare Conference on April 14 at 8:45 am ET, and the 14th Kempen Life Sciences Conference on April 21, with timing to be confirmed. Management will present, and audio webcasts will be available live and archived on the company’s website. Autolus focuses on developing advanced T cell therapies targeting cancer, with a diverse pipeline aimed at treating hematological malignancies and solid tumors.
Positive
- None.
Negative
- None.
News Market Reaction – AUTL
On the day this news was published, AUTL gained 0.72%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Wells Fargo Annual Biotech Forum on April 12 and 13 -
- 21st Annual Needham Virtual Healthcare Conference on April 14 at 8:45am ET -
- 14th Kempen Life Sciences Conference on April 21 - presentation time to be confirmed on the Autolus website -
LONDON, March 29, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in three upcoming investor conferences. An audio webcast of any presentations will be available live. You can access the webcasts via the Events section of the Autolus website. An archived version will also be available through the Company’s website for a limited time following the conference.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit www.autolus.com.
Contact:
Olivia Manser
+44 (0) 7780 471568
o.manser@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com
FAQ
What investor conferences will Autolus Therapeutics attend in April 2022?
When will Autolus present at the 21st Annual Needham Virtual Healthcare Conference?
Where can I find the audio webcasts for Autolus presentations?
What is the focus of Autolus Therapeutics' product development?
What is the stock symbol for Autolus Therapeutics?
